Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?
dc.contributor.author | Bozkurt, Oktay | |
dc.contributor.author | Karaca, Halit | |
dc.contributor.author | Hacibekiroglu, Ilhan | |
dc.contributor.author | Kaplan, Muhammed Ali | |
dc.contributor.author | Duzkopru, Yakup | |
dc.contributor.author | Uysal, Mukremin | |
dc.contributor.author | Berk, Veli | |
dc.date.accessioned | 2024-04-24T17:14:47Z | |
dc.date.available | 2024-04-24T17:14:47Z | |
dc.date.issued | 2016 | |
dc.department | Dicle Üniversitesi | en_US |
dc.description.abstract | Background: The main goal of this study was to examine whether the occurrence of hypothyroidism during sunitinib therapy in patients with metastatic renal cell carcinoma (mRCC) is associated with a better outcome. Methods: The study enrolled 81 patients with pathologically proven mRCC who were treated with sunitinib between March 2008 and June 2013. Thyroid function evaluation comprised (free-thyroxine) FT4 and thyroid-stimulating hormone (TSH) before treatment and at day 1 of each 6-week cycle. Survival analysis was performed using the Kaplan-Meier method, and the differences among the groups were determined using the log-rank test. Results: Hypothyroidism occurred in 30 (37%) of 81 patients within a median 3 months (range 1-18) of treatment initiation. There was a statistically significant correlation between the occurrence of hypothyroidism during treatment and the rate of objective remission (ORR) (hypothyroid patients vs euthyroid patients: 46.7 vs 13.7%, respectively; P = 0.001). Median progression-free survival (PFS) was 10 (95% CI 6.13-13.8) months in the euthyroid patients, and 17 (95% CI 9.33-24.6) months in the hypothyroid patients (P = 0.001). The median overall survival (OS) was 39 (95% CI 25.4-52.5) months in the hypothyroid patients and 20 (95% CI 14.7-25.2) months in the euthyroid patients (P = 0.019). Conclusions: The occurrence of hypothyroidism during treatment in patients was significantly associated with longer PFS, OS and better ORR in the current study. | en_US |
dc.identifier.doi | 10.1179/1973947815Y.0000000039 | |
dc.identifier.endpage | 234 | en_US |
dc.identifier.issn | 1120-009X | |
dc.identifier.issn | 1973-9478 | |
dc.identifier.issue | 3 | en_US |
dc.identifier.pmid | 25948423 | |
dc.identifier.scopus | 2-s2.0-84978701682 | |
dc.identifier.scopusquality | Q3 | |
dc.identifier.startpage | 230 | en_US |
dc.identifier.uri | https://doi.org/10.1179/1973947815Y.0000000039 | |
dc.identifier.uri | https://hdl.handle.net/11468/18196 | |
dc.identifier.volume | 28 | en_US |
dc.identifier.wos | WOS:000380283700015 | |
dc.identifier.wosquality | Q4 | |
dc.indekslendigikaynak | Web of Science | |
dc.indekslendigikaynak | Scopus | |
dc.indekslendigikaynak | PubMed | |
dc.language.iso | en | en_US |
dc.publisher | Taylor & Francis Ltd | en_US |
dc.relation.ispartof | Journal of Chemotherapy | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Hypothyroidism | en_US |
dc.subject | Sunitinib | en_US |
dc.subject | Prognosis | en_US |
dc.subject | Metastatic Renal Cell Cancer | en_US |
dc.title | Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients? | en_US |
dc.title | Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients? | |
dc.type | Article | en_US |